查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864441

抗疟疾药市场按药物类别、给药途径、剂型、通路和最终用户划分－2025年至2032年全球预测

Antimalarial Drugs Market by Drug Class, Route Of Administration, Formulation, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗疟疾药市场规模将成长至 28.4 亿美元，年复合成长率为 6.10%。

关键市场统计数据
基准年 2024 17.6亿美元
预计年份：2025年 18.7亿美元
预测年份 2032 28.4亿美元
复合年增长率 (%) 6.10%

对影响抗疟疾药使用和策略决策的当代临床、政策和供应链环境进行了清晰简洁的概述。

疟疾仍然是全球面临的健康挑战，抗疟疾药对于降低疫区的发病率和死亡率至关重要。本执行摘要了目前影响抗疟疗法的科学、监管和商业性趋势，并重点阐述了临床实践、产品可及性和卫生系统准备情况之间的相互作用。近年来，药物疗效、新出现的抗药性标记以及不断更新的治疗指南等诸多因素交互作用，正在影响临床决策和筹资策略。

除了临床疗效外，抗疟药物的供应模式也受到生产能力、供应链完整性和政策奖励等因素的影响，这些因素决定了疟疾流行地区的药物可近性。儘管公私合营和国际捐助机构的倡议持续推动药物供应，但各国卫生系统在整合新的治疗通讯协定和满足药物监测要求方面仍面临挑战。因此，从临床医生和采购负责人到生产者和政策制定者，相关人员必须应对不断变化的证据基础和物流限制。本概述旨在为决策者提供一份简明指南，帮助他们了解当前的抗疟疾药市场格局，并优先采取策略行动，以维持治疗效果并确保药物的持续可及性。

不断发展的抗药性科学、更新的治疗策略以及供应链的韧性正在共同重塑抗疟疾疗法的研发、采购和部署。

抗疟领域正经历着由科学进步、政策变革和市场力量共同驱动的变革。在科学方面，对抗药性机制和分子监测的深入了解正在推动治疗指南的修订，并激发人们对新型联合治疗的兴趣。同时，诊断技术的进步和综合病例管理方法的改进正在改变需求模式，促进标靶治疗并减少不合理用药。

从监管和政策角度来看，随着监测数据的不断涌现，国家治疗政策的快速更新已成为常态，这要求生产商和采购机构必须具备敏捷性。在商业方面，学名药生产商之间的整合以及与研究机构的策略联盟正在重塑供应关係和生产力计画。同时，近期全球供应链的中断使得供应链韧性成为重中之重，推动了对区域製造地、缓衝库存政策和采购多元化的投资。这些变化共同重塑了药物的研发、采购和部署方式，为致力于维持有效抗疟疗法的相关人员带来了风险和机会。

贸易政策变化和关税如何影响抗疟疾药筹资策略、供应多元化以及向本地化生产转型

美国将于2025年开始加征关税，这为国际抗疟疾药供应体系的采购、生产和成本结构带来了新的挑战。关税壁垒将影响采购决策，并可能加速本地化进程，因为买家和製造商都在寻求关税效率更高的供应链和本地化生产。为此，一些製造商正在考虑转移生产或签订长期合同，以将关税的影响内部化，从而保护脆弱市场的价格稳定。

医疗保健采购方和国家计画不得不重新评估竞标规范和供应商多元化，以减轻潜在的干扰。此外，关税相关的波动凸显了区域製造地以及国内灌装和包装能力的战略重要性，这些能力可以降低受国际贸易紧张局势影响的风险。同时，捐助机构和多边合作伙伴不得不调整资金筹措模式，以应对成本动态的变化，并优先考虑促进可持续获取医疗服务和永续本地能力建设的干预措施。整体而言，关税促使人们重新评估供应链策略，并凸显了能够吸收政策衝击的灵活采购方式的优势。

基于对驱动需求和策略差异化因素的详细分析，包括治疗领域、给药途径、剂型、通路和终端用户环境，得出细分市场洞察。

細項分析所揭示的关键差异应体现在产品开发、分销计划和临床实施策略的製定中。从药物类别来看，市场可分为青蒿素类联合疗法和非青蒿素类疗法。前者包括一些特定的复方製剂，例如蒿甲醚-苯芴醇、青蒿琥酯-阿莫地喹、青蒿琥酯-甲氟喹和青蒿素-哌喹；后者包括一些常规药物，例如Chloroquine、甲氟喹、伯氨喹和奎宁。了解每类药物的治疗定位和抗药性特征对于制定药物选择标准和临床指南至关重要。

给药途径也是关键的区分因素，口服和注射剂型适用于不同的应用情境。口服剂型是门诊治疗和大规模药物管理宣传活动的核心，而注射剂型则是重症疟疾和住院治疗的必需品。製剂形式的选择（例如注射剂、混悬剂、片剂）会影响生产的复杂性、低温运输要求以及患者的依从性。通路，包括医院药房、线上药房和零售药房，为触达最终用户提供了多种途径，并需要不同的商业性和监管策略。最后，将最终用户细分——包括门诊中心、诊所和医院——可以突出需求集中的领域、不同治疗通讯协定环境之间的差异，以及在培训和供应链干预方面投入资金将产生最大影响的领域。

流行病学特征、监管协调以及关键地区的生产能力如何影响抗疟疾疗法的获取途径和战略重点

区域趋势正深刻影响着美洲、欧洲、中东和非洲以及亚太地区的医疗资源取得、监管方式和供应链策略，而这些地区各自具有不同的流行病学特征和卫生系统能力。在美洲，重点往往在于针对性应对、加强监测以及在局部疫情爆发地区和边境地区维持供应连续性，并与当地製造商和区域采购机制合作，以确保稳定的供应。

在欧洲、中东和非洲地区，监管协调工作和捐助者支持的计画与非洲部分地区的高负担环境相交织，在这些地区，药物可及性和抗药性管理仍然是优先事项。对监测基础设施和能力建设的投资可能产生特别显着的影响。在全部区域，复杂的流行病学情势和多重抗药性患者的出现正在推动治疗通讯协定的创新，并加速联合治疗疗法的应用。同时，该地区部分地区强大的学名药生产能力正在影响全球供应流动。这些区域趋势要求在政策参与、采购设计和本地能力建构方面采取差异化的策略，以适应临床需求和卫生系统实际情况。

在复杂的全球市场中，决定谁能确保有效抗疟疾治疗的企业策略、伙伴关係和营运实践至关重要。

透过策略投资、伙伴关係和营运协调，主要企业和机构的行动正在塑造抗疟疾治疗的发展轨迹。药物研发公司持续投资于下一代化合物和新型给药平台，而现有非专利生产商则专注于提高生产效率和优化成本结构，以满足流行市场的持续需求。合作模式日益普遍，官民合作关係促进了后期临床试验、技术转移以及生产和品质保证方面的能力建设。

同时，契约製造生产商和特种製剂供应商在推动快速扩大生产规模和实现国内灌装包装方面发挥关键作用。製药公司与诊断开发商之间的策略联盟也在不断发展，将治疗与病例检测的改进联繫起来。从商业性角度来看，拥有完善的药物监测系统、遵守国际品质标准以及灵活的供应链能力的公司最能有效支持国家计画和国际捐助者。整体而言，市场可能会青睐那些在研发创新、可靠的生产能力以及对目标市场营运的深刻理解之间取得平衡的企业。

为加强抗疟疾药价值链各环节的治疗效果、供应链韧性、监管完整性和相关利益者合作，提出切实可行的策略建议

产业领导者应采取多管齐下的策略，同时提升临床疗效、增强供应链韧性并促进相关人员的合作。首先，增加对抗药性监测、数据共用和适应性临床计画的投入，将有助于维持治疗价值并促进政策的及时调整。其次，透过区域製造伙伴关係和提升灌装包装能力来实现供应链多元化，既能提高对区域需求的应对力，又能降低贸易中断和关税带来的风险。

除了采购和生产之外，各组织还应优先考虑综合产品管理，将可靠的药物监测与医护人员教育结合，以维持药物的合理使用。与监管机构和多边捐助方积极合作，有助于使采购框架与公共卫生目标保持一致。最后，实施用于需求预测、库存视觉化和品质监控的数位化工具，将有助于提升产品生命週期各阶段的决策水准。综上所述，这些努力将建构一种具有韧性的方法，支持有效的治疗方案和抗疟工作的长期永续性。

采用透明的混合调查方法，结合证据综合、与主要相关利益者的访谈以及严格的检验，以确保研究结果的可靠性和实际意义。

本执行摘要的研究采用了混合方法，结合严谨的二手资料综合分析和有针对性的原始研究，以确保其有效性和相关性。二手资料包括同行评审的临床文献、监管指导文件和公共卫生报告，这些资料均经过严格的评估，以确保其方法学品质和实践适用性。原始研究包括对临床医生、采购专业人员、製造企业高管和政策顾问进行结构化访谈，以了解营运观点和实际限制因素。

为整合不同资讯来源并识别一致模式，我们运用了资料三角测量和交叉检验技术。同时，我们也考虑了时间因素和近期政策变化，以确保分析结果反映最新实际情况。在定量资料有限的情况下，我们则运用定性分析来解读趋势并得出策略启示。最后，我们实施了包括专家同侪审查和方法透明化在内的品质保证措施，以增强报告的可信度，并使相关人员对报告的结论和建议充满信心。

结论表明，协调的监测、区域製造投资和营运灵活性对于维持抗疟疾治疗的有效性至关重要。

总之，目前的抗疟疾药市场是一个由科学、监管和物流等诸多因素交织而成的复杂网络，需要采取协调一致、以证据为基础的因应措施。有针对性地投资于抗药性监测、适应性政策制定以及本地化生产和供应链体系，是维持治疗效果和确保公平获取药物的关键所在。从采购设计到本地分销，能够整合临床洞察力和营运灵活性的相关人员，将更有能力应对新出现的挑战，并支持永续的疾病控制。

公共、私营和慈善组织必须继续携手合作，协调奖励，共用数据，并在最关键的领域加强能力建构。透过促进创新，同时专注于建立具有韧性的供应链、提高监管灵活性并妥善管理现有疗法，国际社会可以持续推动抗击疟疾的工作，保护弱势群体免受可预防疾病和死亡的侵害。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在偏远社区，单剂量他非诺喹在根治间日疟原虫疟疾的应用日益广泛
  • 儿科颗粒状抗疟药製剂可提高撒哈拉以南非洲地区的治疗顺从性
  • 在亚洲主要市场，非专利青蒿素联合疗法的成长面临价格压力和监管漏洞。
  • 增加对下一代三联抗疟疗法的投资，以对抗东南亚的多重抗药性疟原虫株。
  • 将数位药物依从性技术与行动医疗平台结合，用于监测农村地区的抗疟疾治疗效果

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依药物类别分類的抗疟疾药市场

  • 青蒿素类联合疗法
    • 蒿甲醚-蒿芴醇
    • 青蒿琥酯/阿莫地喹
    • 青蒿琥酯/甲氟喹
    • 青蒿素-哌喹
  • 非青蒿素疗法
    • Chloroquine
    • 甲氟喹
    • 伯氨喹
    • 奎宁

第九章 依给药途径分類的抗疟疾药市场

  • 注射
  • 口服

第十章 以剂型分類的抗疟疾药市场

  • 注射
  • 暂停
  • 药片

第十一章 按通路分類的抗疟疾药市场

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 依最终用户分類的抗疟疾药市场

  • 门诊治疗中心
  • 诊所
  • 医院

第十三章 各地区抗疟疾药市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章抗疟疾药市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国抗疟疾药市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Novartis International AG
    • GlaxoSmithKline plc
    • Sanofi SA
    • Cipla Limited
    • Viatris Inc.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Limited
    • Ipca Laboratories Limited
    • Dr. Reddy's Laboratories Limited
    • Bayer Aktiengesellschaft
Product Code: MRR-F97DD5A7DAEF

The Antimalarial Drugs Market is projected to grow by USD 2.84 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.76 billion
Estimated Year [2025] USD 1.87 billion
Forecast Year [2032] USD 2.84 billion
CAGR (%) 6.10%

A clear, concise introduction to the contemporary clinical, policy, and supply chain environment shaping antimalarial drug use and strategic decision-making

Malaria remains a persistent global health challenge, and antimalarial drugs are central to reducing morbidity and mortality in affected populations. This executive summary synthesizes current scientific, regulatory, and commercial dynamics shaping antimalarial therapeutics, emphasizing the intersection of clinical practice, product availability, and health system preparedness. Recent years have witnessed a complex interplay between drug efficacy concerns, emergence of resistance markers, and evolving treatment guidelines, which together influence clinical decision-making and procurement strategies.

Beyond clinical efficacy, the landscape is influenced by manufacturing capacity, supply chain integrity, and policy incentives that determine access in endemic regions. Public-private collaborations and international donor initiatives continue to drive distribution efforts, while national health systems wrestle with integration of new treatment protocols and pharmacovigilance requirements. As a result, stakeholders ranging from clinicians and procurement officers to manufacturers and policymakers must navigate shifting evidence and logistical constraints. This overview provides a concise orientation for decision-makers seeking to understand the contemporary context of antimalarial drugs and to prioritize strategic actions that preserve treatment effectiveness and ensure sustained access.

How evolving resistance science, updated treatment policies, and supply chain resilience are jointly reshaping development, procurement, and deployment of antimalarial therapies

The antimalarial space is undergoing transformative shifts driven by scientific advances, policy change, and market forces. On the scientific front, improved understanding of resistance mechanisms and molecular surveillance has prompted revisions to therapeutic guidance and accelerated interest in novel combination therapies. Concurrently, enhanced diagnostics and integrated case management approaches are altering demand patterns, encouraging targeted treatment and reducing inappropriate drug use.

From a regulatory and policy perspective, rapid updates to national treatment policies have become more common as surveillance data emerges, requiring manufacturers and procurement agencies to be more agile. Commercially, consolidation among generics manufacturers and strategic alliances with research institutions are reshaping supply relationships and capacity planning. Meanwhile, supply chain resilience has risen in priority after recent global disruptions, driving investments in regional manufacturing, buffer stock policies, and diversified sourcing. Taken together, these shifts are redefining how drugs are developed, procured, and deployed, creating both risks and opportunities for stakeholders committed to sustaining effective antimalarial therapy.

Implications of trade policy changes and tariffs on procurement strategies, supplier diversification, and the push toward regional manufacturing for antimalarial supplies

The imposition of tariffs by the United States in 2025 introduced new considerations for procurement, manufacturing, and cost structures within the international antimalarial supply ecosystem. Tariff barriers influence sourcing decisions and may accelerate regionalization efforts as purchasers and manufacturers seek tariff-efficient supply chains and localized production. In response, some manufacturers have evaluated shifting production footprints or negotiating long-term contracts that internalize tariff impacts to protect price stability in vulnerable markets.

Healthcare purchasers and national programs have needed to reassess tender specifications and supplier diversification to mitigate potential disruptions. Moreover, tariff-related changes have reinforced the strategic importance of regional manufacturing hubs and in-country fill-and-finish capabilities, which can reduce exposure to international trade frictions. At the same time, donor agencies and multilateral partners have had to adapt funding models to accommodate altered cost dynamics, prioritizing interventions that preserve access while promoting sustainable local capacity. Overall, tariffs have catalyzed a reevaluation of supply chain strategies and underscored the advantage of flexible procurement approaches that can absorb policy-driven shocks.

Detailed segmentation insights highlighting therapeutic classes, administration routes, formulations, distribution channels, and end-user settings that drive differentiated demand and strategy

Segmentation analysis reveals critical nuances that should inform product development, distribution planning, and clinical adoption strategies. When considering drug class, the market is partitioned between artemisinin-based combination therapies and non-artemisinin therapies, with the former encompassing specific combinations such as artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, and dihydroartemisinin-piperaquine, and the latter including classic agents like chloroquine, mefloquine, primaquine, and quinine; understanding therapeutic niches and resistance profiles across those classes is essential for formulary decisions and clinical guidelines.

Route of administration is another differentiator, with oral and injectable modalities presenting distinct use cases: oral formulations are central to outpatient management and mass drug administration campaigns, whereas injectables are critical for severe malaria and inpatient care. Formulation considerations-whether injectables, suspensions, or tablets-affect manufacturing complexity, cold chain needs, and adherence outcomes. Distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, create divergent pathways to end users and require tailored commercial and regulatory approaches. Finally, end user segmentation across ambulatory care centers, clinics, and hospitals highlights where demand concentrates, how treatment protocols vary by setting, and where investments in training and supply chain interventions will have the greatest impact.

How regional epidemiology, regulatory harmonization, and manufacturing capacity across major global regions shape access pathways and strategic priorities for antimalarial therapies

Regional dynamics deeply influence access, regulatory approaches, and supply chain strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting distinct epidemiological profiles and health system capacities. In the Americas, the focus often lies on targeted control measures, surveillance strengthening, and maintaining supply continuity for localized outbreaks and border areas; partnership with local manufacturers and regional procurement mechanisms plays a role in ensuring steady availability.

In Europe, the Middle East & Africa, regulatory harmonization efforts and donor-supported programs intersect with high-burden settings in parts of Africa, where access and resistance management remain priorities; investments in surveillance infrastructure and capacity building are particularly impactful. Across Asia-Pacific, complex epidemiology and pockets of multidrug resistance have driven innovation in treatment protocols and accelerated adoption of combination therapies, while robust generic manufacturing in parts of the region affects global supply flows. Collectively, these regional patterns necessitate differentiated strategies for policy engagement, procurement design, and local capacity strengthening to match clinical needs and health system realities.

Corporate strategies, partnerships, and operational practices that are determining who can reliably deliver effective antimalarial solutions in complex global markets

Key corporate and institutional behaviors are shaping the trajectory of antimalarial therapeutics through strategic investments, partnerships, and operational adjustments. Innovator companies continue to invest in next-generation compounds and novel delivery platforms, while established generic manufacturers focus on scaling production efficiency and improving cost structures to meet sustained demand in endemic markets. Collaborative models are increasingly common, with public-private partnerships facilitating late-stage clinical studies, technology transfer, and capacity building in manufacturing and quality assurance.

At the same time, contract manufacturers and specialty formulation providers play a vital role in enabling rapid scale-up and in-country fill-and-finish operations. Strategic alliances between pharmaceutical firms and diagnostic developers are also emerging to align treatment with improved case detection. From a commercial perspective, companies that combine robust pharmacovigilance, compliance with international quality standards, and responsive supply chain capabilities are best positioned to support national programs and international donors. Overall, the market rewards organizations that balance R&D innovation with reliable manufacturing and deep operational understanding of endemic markets.

Actionable strategic recommendations for strengthening therapeutic efficacy, supply chain resilience, regulatory alignment, and stakeholder collaboration across the antimalarial value chain

Industry leaders should adopt a multi-pronged strategy that concurrently advances clinical efficacy, supply resilience, and stakeholder collaboration. First, investment in resistance surveillance, data sharing, and adaptive clinical programs will preserve therapeutic value and inform timely policy adaptations. Second, diversifying supply chains through regional manufacturing partnerships and strengthened fill-and-finish capabilities will reduce exposure to trade disruptions and tariffs while improving responsiveness to localized demand.

Beyond procurement and manufacturing, organizations should prioritize integrated product stewardship, coupling reliable pharmacovigilance with provider education to sustain appropriate use. Engaging proactively with regulatory bodies and multilateral donors enables alignment of procurement frameworks with public health goals. Finally, adopting digital tools for demand forecasting, inventory visibility, and quality monitoring enhances decision-making across the product lifecycle. Taken together, these actions create a resilient approach that supports effective treatment delivery and long-term viability of antimalarial interventions.

A transparent mixed-methods research approach combining evidence synthesis, primary stakeholder interviews, and rigorous validation to ensure credible insights and practical relevance

The research underpinning this executive summary deployed a mixed-methods approach combining rigorous secondary evidence synthesis with targeted primary inquiry to ensure validity and relevance. Secondary inputs included peer-reviewed clinical literature, regulatory guidance documents, and public health reports that were critically appraised for methodological quality and applicability to practice. Primary research involved structured interviews with clinicians, procurement specialists, manufacturing executives, and policy advisors to capture operational perspectives and real-world constraints.

Data triangulation and cross-validation techniques were applied to reconcile divergent sources and to identify consistent patterns. Attention was paid to temporal factors and recent policy changes to ensure the analysis reflects the most current realities. Where quantitative data were limited, qualitative insights were used to contextualize trends and infer strategic implications. Finally, quality assurance measures, including expert peer review and methodological transparency, were implemented to enhance credibility and to provide stakeholders with confidence in the report's findings and recommendations.

Concluding insights emphasizing the imperative of coordinated surveillance, regional manufacturing investments, and operational agility to sustain antimalarial treatment effectiveness

In conclusion, the antimalarial drugs landscape is defined by a confluence of scientific, regulatory, and logistical dynamics that require coordinated, evidence-driven responses. Resistance surveillance, adaptive policy-making, and targeted investments in regional manufacturing and supply chain systems are central to preserving treatment effectiveness and ensuring equitable access. Stakeholders who integrate clinical intelligence with operational agility - from procurement design to on-the-ground distribution - will be better positioned to respond to emerging challenges and to support sustainable disease control efforts.

Moving forward, the emphasis should remain on collaboration across public, private, and philanthropic actors to align incentives, share data, and build capacity where it matters most. By focusing on resilient supply chains, responsive regulatory engagement, and stewardship of existing therapeutics while fostering innovation, the global community can sustain progress against malaria and protect vulnerable populations from preventable illness and death.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increased adoption of single-dose tafenoquine for radical cure of Plasmodium vivax malaria in remote communities
  • 5.2. Emergence of pediatric-friendly antimalarial granule formulations improving treatment adherence in sub-Saharan Africa
  • 5.3. Growth of generic artemisinin combination therapies facing pricing pressure and regulatory variations across key Asian markets
  • 5.4. Rising investments in next-generation triple combination antimalarial regimens to combat multi-drug resistant strains in Southeast Asia
  • 5.5. Integration of digital adherence technologies and mobile health platforms to monitor antimalarial treatment outcomes in rural zones

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimalarial Drugs Market, by Drug Class

  • 8.1. Artemisinin Based Combination Therapy
    • 8.1.1. Artemether Lumefantrine
    • 8.1.2. Artesunate Amodiaquine
    • 8.1.3. Artesunate Mefloquine
    • 8.1.4. Dihydroartemisinin Piperaquine
  • 8.2. Non Artemisinin Therapies
    • 8.2.1. Chloroquine
    • 8.2.2. Mefloquine
    • 8.2.3. Primaquine
    • 8.2.4. Quinine

9. Antimalarial Drugs Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral

10. Antimalarial Drugs Market, by Formulation

  • 10.1. Injectables
  • 10.2. Suspensions
  • 10.3. Tablets

11. Antimalarial Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Antimalarial Drugs Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Hospitals

13. Antimalarial Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antimalarial Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antimalarial Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis International AG
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. Sanofi S.A.
    • 16.3.4. Cipla Limited
    • 16.3.5. Viatris Inc.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Sun Pharmaceutical Industries Limited
    • 16.3.8. Ipca Laboratories Limited
    • 16.3.9. Dr. Reddy's Laboratories Limited
    • 16.3.10. Bayer Aktiengesellschaft

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIMALARIAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 300. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 301. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 304. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 305. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)

TABL